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Background: Certain amino acids are decreased in humans with inflammatory bowel disease (IBD)
and supplementation with the same amino acids has shown beneficial effects in animal models of
IBD. Currently, the amino acid status of dogs with protein-losing enteropathy (PLE) is unknown.
Hypothesis/Objective: To determine if serum amino acid concentrations are abnormal in dogs
with PLE and correlated with clinical and laboratory variables and outcome.
Animals: Thirty client-owned dogs diagnosed with PLE and 12 apparently healthy dogs seen at
Bristol Veterinary School.
Methods: Retrospective study using stored residual serum from fasted dogs with PLE, collected at
the time of diagnostic investigation and from apparently healthy dogs. Serum was analyzed for 30
amino acids using an automated high-performance liquid chromatography amino acid analyzer.
Results: Serum tryptophan concentrations were significantly decreased in dogs with PLE (median,
22 nmol/mL; range, 1–80 nmol/mL) compared with apparently healthy control dogs (median,
77.5 nmol/mL; range, 42–135 nmol/mL, P< .001). There were no significant differences in the
remaining 29 serum amino acids between dogs with PLE and apparently healthy. Serum trypto-
phan concentrations were also significantly correlated with serum albumin concentrations in dogs
with PLE (P5 .001, R2 50.506).
Conclusions and Clinical Importance: Decreased serum tryptophan concentration might play a
role in the pathogenesis of canine PLE or be a consequence of the disease.
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1 | INTRODUCTION
There is a role for amino acids in gastrointestinal (GI) health. Amino
acids such as arginine, glutamine, glycine, cysteine, N-acetylcysteine,
and proline have functions in the GI tract such as attenuation of gut
damage, support of intestinal barrier function and integrity, reduction
in oxidative stress, restoration of mucosal immune homeostasis, and
optimization of function by normalizing or reducing inflammatory
cytokine secretion and increasing immune regulatory cytokine
concentrations.1–4 Recent studies have increasingly focused on the role
of amino acids in the pathogenesis and treatment of humans with
inflammatory bowel disease (IBD) and animal models of this disease.
There are altered serum amino acid concentrations in humans and
animal models of IBD.5,6 After 7 days of dextran sodium sulfate (DSS)
induced colitis, mice had decreased concentrations of tryptophan, glu-
tamic acid and aspartic acid.6 In addition, tryptophan-deficient mice
had more severe colitis when it was induced with DSS.7 Humans with
ulcerative colitis, a type of IBD, have decreased serum concentrations
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of glutamic acid, glutamine, methionine, tryptophan and histidine com-
pared with healthy controls.8 Similarly, other studies have confirmed
low serum tryptophan concentrations in humans with IBD.5,9,10 There
is an anti-inflammatory effect of dietary intervention with tryptophan
or tryptophan metabolites in experimental models of colitis, with sup-
plementation ameliorating clinical signs, improving weight gain and his-
tological scores and decreasing gut permeability and expression of pro-
inflammatory cytokines.11,12 Similarly, supplementation with glutamine,
arginine, N-acetylcysteine, and glycine in animal models of IBD has
beneficial effects such as reduced intestinal permeability and decreased
production of proinflammatory cytokines.13–16
Dogs with protein-losing enteropathy (PLE) have increased loss of
protein from the intestinal tract resulting in hypoproteinemia. These
animals likely also have a higher requirement for dietary protein
because of increased demand from ongoing inflammation. Therefore,
dogs with PLE might be at increased risk of developing an essential
amino acid deficiency, especially as they might not be able to replenish
their increased losses or meet their increased demands because of
hyporexia or anorexia caused by their disease. Therefore, given the
important functions of certain amino acids in the GI tract, a deficiency
might contribute to or exacerbate disease in these dogs.
The aims of our study were to determine, (1) whether serum amino
acid concentrations in dogs with PLE differ from healthy dogs and (2)
to correlate any significant changes with age at diagnosis, clinical signs,
and canine chronic enteropathy activity index (CCEAI)17; laboratory
variables, and survival.
2 | MATERIALS AND METHODS
2.1 | Retrospective study criteria for case selection
The medical records at the Bristol Veterinary School were searched for
dogs presented between January 2012 and October 2017 with a diag-
nosis of PLE. All medical records then were reviewed by one of the
authors (A. Kathrani). Those dogs that had panhypoproteinemia with
hypocholesterolemia but did not have histopathology of GI biopsies
performed were still included. In addition, dogs that had solely hypoal-
buminemia required appropriate diagnostic investigation including urine
protein creatinine ratio to rule out other causes and histopathology of
GI biopsies to confirm an underlying etiology consistent with PLE for
inclusion into the study. The minimum diagnostic evaluation performed
on each dog included a complete blood count, serum biochemistry,
serum cobalamin, and folate concentrations and trans-abdominal ultra-
sound examination. Of the 30 dogs included in the PLE group, the
following number had additional diagnostic procedures performed when
indicated by the history, physical examination, and ultrasound examina-
tion findings: collection of intestinal biopsy specimens by upper GI
endoscopy in 28 dogs (93%), with an additional 12 dogs (40%) having
lower GI endoscopy, pancreatic testing (canine pancreatic lipase immu-
noreactivity in 15 dogs [50%] and trypsin-like immunoreactivity in
18 [60%]), basal cortisol concentration or ACTH stimulation test in
20 dogs (67%), preprandial or preprandial and postprandial bile acid con-
centrations in 20 dogs (67%), fecal parasitology using zinc sulfate flotation
with centrifugation in 24 dogs (80%), fecal culture (for Salmonella, Cam-
pylobacter, and Clostridium difficile) in 22 dogs (73%), empirical deworm-
ing in 27 dogs (90%) and urine protein creatinine ratio in 24 dogs (80%).
A fasted serum sample stored in 2208C from the time of diagnos-
tic investigation for each dog was retrieved from the archive at Bristol
Veterinary School and sent to the Amino Acid Laboratory at the Uni-
versity of California, Davis on dry ice for serum amino acid analysis.
2.2 | Data collection
Medical records were reviewed for each dog and the signalment; clini-
cal history including duration of clinical signs, appetite, lethargy, weight
loss, vomiting, and diarrhea; complete diet history; BCS; and, results of
diagnostic tests including laboratory findings, transabdominal ultra-
sound examination findings, endoscopic findings, and histopathology
report were collected. The CCEAI was calculated for dogs with chronic
inflammatory enteropathy.17
To determine if the diet each dog was consuming complied with the
recommendations of the World Small Animal Veterinary Association
(WSAVA) Global Nutrition Committee, each manufacturer was con-
tacted and asked to reply to the 8 questions outlined in section A of the
web-link (WSAVA Global Nutrition Committee Guidelines: http://www.
wsava.org/sites/default/files/Recommendations%20on%20Selecting
%20Pet%20Foods.pdf). Diets were considered to meet the recom-
mendations outlined by the WSAVA Global Nutrition Committee if
the manufacturer could satisfactorily address all of the questions.
2.3 | Selection of control dogs
Serum samples from 12 dogs from which food was withheld for 10–12
hours, which were considered to be apparently healthy based on his-
tory, physical examination, complete blood count, and biochemistry
panel were selected as controls. Dogs that were evaluated as appa-
rently healthy were blood donors (4 dogs) or undergoing routine dental
procedures (8 dogs). Serum was stored in 2208C for a similar time
period as the PLE dogs and was retrieved from the archive at the Bris-
tol Veterinary School and sent to the Amino Acid Laboratory at the
University of California, Davis on dry ice for serum amino acid analysis.
2.4 | Serum amino acid analysis
Serum concentrations of taurine, L-aspartic acid, L-threonine, L-serine, L-
asparagine, L-glutamic acid, L-glutamine, glycine, L-alanine, L-citrulline, L-
a-amino-n-butyric acid, L-valine, L-cysteine, L-methionine, L-isoleucine,
L-leucine, L-tyrosine, b-alanine, L-phenylalanine, D-hydroxylysine, L-orni-
thine, L-lysine, 1-methyl-L-histidine, L-histidine, tryptophan, 3-methyl-L-
histidine, L-carnosine, L-arginine, L-hydroxyproline, and L-proline were
analyzed with an automated high-performance liquid chromatography
amino acid analyzer (Biochrom 30, Biochrom Ltd, Holliston, Massachu-
setts), using a method described elsewhere.18
The R2 of calculated standard curves of major amino acids were-
>0.9995. Internal standard recovery range of each sample was within
97%-100% and relative variances of major amino acids between dupli-
cates were <2%. The detection limit of major amino acids was 0.1
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nmol/mL with 50 lL load and recovery rates of spiking standards (addi-
tion of 200 nmol/mL) were 97%-102%.
2.5 | Ethical considerations
Stored residual blood was used in our study and the University of Bris-
tol granted ethical approval for the study (VIN/17/026).
2.6 | Data analysis and statistics
Analyses were performed using a computer software package (IBM
SPSS Statistics Version 23). The Mann-Whitney U test and Fisher’s
exact test were used to determine if there were any significant differ-
ences in age and sex/neuter status between the PLE and apparently
healthy dogs, respectively.
The Shapiro-Wilk test was used to determine if the concentrations
of each of the 30 amino acids were normally distributed. For those
amino acids that were normally distributed, a t-test was used to deter-
mine if there were any significant differences between concentrations
in the dogs with PLE versus the apparently healthy dogs. For amino
acids that were not normally distributed, a Mann-Whitney U test was
used to determine if there were any significant differences between
concentrations in the dogs with PLE versus the apparently healthy
dogs. A Bonferroni correction was applied, so that significance was
defined as P< .0017.
For those amino acids that were significantly different between
dogs with PLE and those that were apparently healthy, a simple logistic
regression analysis was used to determine if there were any significant
associations between the amino acid concentrations in the PLE dogs
and age at diagnosis; chronicity of clinical signs; appetite, percentage
body weight loss; body condition score (BCS); serum albumin, globulin,
cholesterol, cobalamin, and folate concentrations; CCEAI; whether the
diet consumed at diagnosis met the WSAVA Global Nutrition Commit-
tee Guidelines, survival versus death because of PLE, days to death or
euthanasia because of PLE and serum sample storage time in 2208C.
Variables associated with the amino acid concentrations in the PLE
dogs with P< .2 in simple linear regression were entered into multivari-
able analyses. In the multivariable regression models, analyses were
performed in a backward stepwise manner. All variables with P< .2
were initially included, and the variable with the highest P-value was
removed until all remaining variables had a P< .05.
3 | RESULTS
3.1 | Dogs
Thirty dogs with PLE were included in the study: 1 intact male, 14 neu-
tered males, and 15 neutered females. The age of the dogs ranged
from 1.2 to 13.5 years, with a median age of 7.9 years. Breeds included
cross breed (3), Yorkshire Terrier (2), Staffordshire Bull Terrier (2),
Labrador Retriever (2), Lurcher (2), Shetland Sheepdog (2), Cocker
Spaniel (2), Jack Russell Terrier (2), English Bulldog (2), and 1 each of
the following breeds: Japanese Akita, Great Dane, Cavalier King
Charles Spaniel, Border Terrier, Newfoundland, Sloughi, German
Shepherd Dog, Border Collie, Hungarian Vizsla, Greyhound, and a
West Highland White Terrier. Body condition score ranged from 1/9
to 7–8/9, with a median of 3–4/9.
Twelve dogs that were apparently healthy were included in the
study: 2 intact males, 4 neutered males, 1 intact female, and 5 neutered
females. The age of the dogs ranged from 1 to 12 years, with a median
of 8.5 years. Breeds included Cross Breed (3), Labrador Retriever (3),
Greyhound (2), and 1 each of the following breeds: English Springer
Spaniel, Border Terrier, Border Collie, and Siberian Husky.
There were no significant differences in age and sex/neuter status
between the PLE and apparently healthy dogs (P> .15).
3.2 | History
Duration of clinical signs for all PLE dogs ranged between 1 day and
570 days (median, 60 days). Twenty dogs (67%) were reported to have
lost weight (median 9.35% body weight loss, range 4%-28%), 2 dogs
(7%) were reported to be weight stable, and weight changes were
unreported for 8 dogs (27%). Four dogs (13%) were anorexic, 10 dogs
(33%) were hyporexic, 11 dogs (37%) had an unchanged appetite, 3
(10%) were reported to be polyphagic, and appetite was unreported in
2 (7%) at the time of presentation. Twenty-seven (90%) dogs were
reported to have diarrhea and 3 (10%) were reported to have normal
feces at the time of presentation. Thirteen dogs (43%) were reported
to be vomiting and for 17 (57%) vomiting was not a feature of their dis-
ease. Twenty dogs (67%) were eating a diet that met the recommenda-
tions outlined by the WSAVA Global Nutrition Committee at the time
of presentation whereas 6 dogs (20%) were not and diet history was
unreported in 4 dogs (13%). The median CCEAI was 8 with a range of
3–15.
3.3 | Histologic diagnosis
Twenty-eight of the 30 PLE dogs (93%) had histopathology of intestinal
biopsies performed. All biopsy specimens were collected using endos-
copy. One dog was diagnosed with small cell lymphoma and 1 dog with
primary lymphangiectasia. Twenty-six dogs (87%) were diagnosed with
chronic inflammatory enteropathy; 8 (27%) had lymphoplasmacytic and
eosinophilic enteritis, 6 (20%) had lymphoplasmacytic enteritis, 3 (10%)
had eosinophilic enteritis, 3 (10%) had lymphoplasmacytic, eosinophilic,
and neutrophilic enteritis, 3 (10%) had plasmacytic and eosinophilic
enteritis, 2 (7%) had lymphoplasmacytic and neutrophilic enteritis, and
1 (3%) had plasmacytic enteritis. Ten of the 26 dogs (38%) with chronic
inflammatory enteropathy had concurrent lacteal dilatation on histopa-
thology and 5 (19%) had crypt abscesses. Of the 2 dogs with PLE that
did not have intestinal biopsies performed, one was empirically treated
with prednisolone and chlorambucil as the owners declined endoscopy
and the 2nd dog was diagnosed with salmonellosis on fecal culture.
Colonic biopsies were performed in 12 dogs (40%); 5 (17%) had
lymphoplasmacytic colitis, 3 (10%) were within normal limits, and 1 had
each of the following (3%); lymphocytic, lymphoplasmacytic, and eosin-
ophilic, lymphoplasmacytic and neutrophilic, and plasmacytic and
eosinophilic.
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3.4 | Serum albumin, globulin, cholesterol, cobalamin,
and folate concentrations
All dogs with PLE had hypoalbuminemia (median, 17.4 g/L; range,
11.7–29.3 g/L; reference range, 32–38 g/L), consistent with inclusion
criteria. Twenty-one dogs (70%) had hypoglobulinemia, 8 dogs (27%)
had globulin concentrations within the reference range, and 1 dog (3%)
had concentrations above the reference range (median, 16.5 g/L; range,
9.6–36.8 g/L; reference range, 20–35 g/L). Nineteen dogs (63%) had
hypocholesterolemia, 5 dogs (17%) had cholesterol within the refer-
ence range, and cholesterol was not measured in 6 dogs (20%; mean,
2.75 mmol/L; SD, 1.08 mmol/L; reference range, 3.5–7.0 mmol/L). Six-
teen dogs (53%) had cobalamin concentrations below the reference
range, 10 dogs (33%) had concentrations within the reference range,
and 4 (13%) were above the reference range; 3 of the latter dogs had
received parenteral cyanocobalamin before analysis (median, 193.5
pmol/L; range, 109–1476 g/L; reference range, 200–408 g/L). Four-
teen dogs (47%) had folate concentrations below the reference range,
9 dogs (30%) had concentrations within the reference range, 6 (20%)
were above the reference range, and 1 dog (3%) did not have a mea-
surement performed (mean, 17.0 nmol/L; SD, 10.56 nmol/L; reference
range, 12.0–30.0 nmol/L).
3.5 | Outcome
Thirteen of the 30 PLE dogs (43%) died or were euthanized because of
the disease; 2 died (7%) and 11 (37%) were euthanized. Two (7%) were
euthanized before discharge from the hospital and 11 (37%) were
euthanized or died after (median days of survival after discharge from
hospital, 18; range 6–180 days). Four of the 30 PLE dogs (13%) were
euthanized because of diseases unrelated to their PLE; 2 of these dogs
were euthanized 4 years and 1 dog 1.8 years after initial discharge
from the hospital. Thirteen of the PLE dogs (43%) were still alive at the
time of our study (median, 0.6 years; range 0.1–4.0 years).
3.6 | Serum amino acid concentrations
Serum tryptophan concentrations were significantly lower in dogs with
PLE compared with apparently healthy dogs (PLE: median, 22 nmol/
mL; range, 1–80 nmol/mL; apparently healthy: median, 77.5 nmol/mL;
range, 42–135 nmol/mL, P< .001, Table 1, and Figure 1).
There were no significant differences in the remaining 29 serum
amino acids between dogs with PLE and apparently healthy (Table 1).
3.7 | Correlation of serum tryptophan concentrations
with various variables in the PLE dogs
In the simple linear regression analyses, age at diagnosis; appetite; per-
centage body weight loss; BCS; serum folate concentration; whether
the diet consumed at diagnosis met the WSAVA Global Nutrition Com-
mittee Guidelines; survival versus death because of PLE; days to death
or euthanasia because of PLE and serum sample storage time in 2208C
did not significantly affect serum tryptophan concentrations in dogs
with PLE (P> .2). The following variables were significantly correlated
with serum tryptophan concentrations in dogs with PLE in the simple
linear regression models: chronicity of clinical signs (P5 .020); serum
albumin concentration (P< .001); serum globulin concentration
(P5 .012); serum cholesterol concentration (P5 .037); serum cobalamin
concentration (P5 .015); and CCEAI (P5 .025). Therefore, these varia-
bles, together with serum folate concentration as this variable had a P-
value of <.2 in the univariable analysis were analyzed further in the
multiple linear regression models. The multiple linear regression models
showed that only serum albumin concentration was significantly corre-
lated with serum tryptophan concentration in dogs with PLE (P5 .001,
R2 [coefficient of determination from linear regression analysis]5
0.506) (Figure 2).
4 | DISCUSSION
In our study, serum tryptophan concentrations were significantly
decreased in 30 dogs with PLE compared with 12 apparently healthy
dogs. Tryptophan is a dietary essential amino acid in dogs; it is impor-
tant for protein synthesis as well as serving as a precursor for additional
bioactive compounds such as kynurenine, serotonin, melatonin, and
picolinic acid.19 The kynurenine pathway comprises at least 90% of
tryptophan catabolism.19,20 The enzyme indoleamine 2,3, dioxygenase
1 (IDO-1) is the initial rate-limiting step in the pathway for the oxida-
tion of tryptophan to kynurenine.19 Increased IDO-1 expression in
human IBD is associated with lower serum tryptophan concentrations
and a higher serum kynurenine tryptophan ratio because of increased
tryptophan catabolism.9 Therefore, decreased serum tryptophan con-
centrations in dogs with PLE in our study might be because of a similar
mechanism of increased IDO-1 expression in the intestinal tract result-
ing in increased catabolism of tryptophan. However, further studies
measuring concurrent serum kynurenine in dogs with PLE and expres-
sion of IDO-1 in intestinal biopsies would be needed to confirm this
mechanism as the cause of decreased serum tryptophan concentrations
in dogs with PLE.
Studies have also shown an association between serum tryptophan
concentrations and disease activity in humans with IBD.5,9 Although
our study did not document an association between CCEAI or outcome
and serum tryptophan concentrations in PLE dogs, there was a signifi-
cant correlation with serum albumin concentrations. Therefore, as
serum albumin concentration is an indicator of the severity of loss from
the GI tract, our study showed that serum tryptophan concentrations
are worse in those dogs with PLE with increased loss and therefore
could be an indicator of severity of inflammation at the level of the
intestinal tract because of increased IDO-1 expression. However, addi-
tional studies would be needed to confirm this hypothesis. Although
tryptophan is reversibly bound to albumin in serum resulting in bound
and free fractions, our study measured only free tryptophan in serum
and therefore is unlikely to have been directly affected by the serum
albumin concentrations. In addition, serum concentrations of free tryp-
tophan in humans with chronic renal failure were shown to be unin-
fluenced by serum protein concentrations and the free fraction was
normal in those patients with hypoalbuminemia.21 Therefore, our study
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demonstrated that in dogs with PLE, as serum albumin decreases,
serum tryptophan concentrations decrease. Decreasing albumin con-
centrations are typically associated with more severe disease in dogs
with PLE. Therefore, serum tryptophan concentration might also be an
indicator of disease severity
An additional possibility for decreased serum tryptophan concen-
trations in dogs with PLE in our study could have been because of the
diet the dogs were consuming. Unfortunately, the correlation between
dietary tryptophan intake and serum concentrations was not able to be
determined in our study, however, further studies assessing the serum
kynurenine tryptophan ratio might help to avert any potential bias gen-
erated by differences in individual dietary intake.22,23 Another impor-
tant limitation of our study includes the absence of published reference
ranges for serum amino acids in dogs. Serum was chosen to measure
TABLE 1 Serum amino acid concentrations in dogs with PLE and apparently healthy dogs
Serum amino acid
Apparently healthy
median (range) or
mean (SD)
PLE median (range)
or mean (SD) P-value
Tryptophan (nmol/mL) 77.5 (42–135) 22 (1–80) <.001
Taurine (nmol/mL) 178 (110–272) 169 (70–404) .48
L-Aspartic acid (nmol/mL) 27.5 (6–152) 21.5 (7–287) .75
L-Threonine (nmol/mL) 296.5 (93.34) 299.4 (117.77) .94
L-Serine (nmol/mL) 174 (87–403) 160.5 (83–584) 1.00
L-Asparagine (nmol/mL) 49.5 (14–575) 54.5 (20–172) .36
L-Glutamic acid (nmol/mL) 102.5 (71–425) 97.5 (35–502) .30
L-Glutamine (nmol/mL) 586.83 (303.67) 415.3 (265.98) .08
Glycine (nmol/mL) 286 (176–534) 233 (128–537) .13
L-Alanine (nmol/mL) 580 (363-1,235) 559.5 (195-1,424) .67
L-Citrulline (nmol/mL) 51.5 (18–174) 26.5 (10–137) .02
L-a-Amino-n-butyric acid (nmol/mL) 16 (5–56) 31 (1–122) .04
L-Valine (nmol/mL) 222.5 (123–446) 275.5 (125–624) .54
L-Cysteine (nmol/mL) 0.5 (0–5) 0 (0–8) .24
L-Methionine (nmol/mL) 29 (1–71) 36.5 (0–129) .37
L-Isoleucine (nmol/mL) 82.5 (44–163) 95 (50–250) .21
L-Leucine (nmol/mL) 169 (100–828) 183 (79-1,015) .77
L-Tyrosine (nmol/mL) 64.5 (39–254) 50.5 (12–338) .21
b-Alanine (nmol/mL) 2 (0–38) 3 (0–33) .83
L-Phenylalanine (nmol/mL) 74 (38–184) 80 (24–277) .79
D-Hydroxylysine (nmol/mL) 2.5 (0–22) 3 (0–13) .77
L-Ornithine (nmol/mL) 17 (12–82) 25.5 (6–133) .33
L-Lysine (nmol/mL) 186 (77-2,262) 234 (21-1,873) .82
1-Methyl-L-histidine (nmol/mL) 14 (5–157) 26 (6–163) .25
L-Histidine (nmol/mL) 88.9 (17.28) 78.6 (31.70) .30
3-Methyl-L-histidine (nmol/mL) 11.6 (5.21) 16.9 (7.78) .04
L-Carnosine (nmol/mL) 33.5 (13–152) 25.5 (6–112) .47
L-Arginine (nmol/mL) 210 (110-1,969) 191 (34-1,450) .40
L-Hydroxyproline (nmol/mL) 36 (0–127) 11.5 (0–57) .005
Proline (nmol/mL) 270 (146–767) 186 (67–744) .07
Serum amino acid concentrations in 30 dogs with PLE and 12 apparently healthy dogs; median and range are listed for those amino acids that were
not normally distributed and mean and SD is listed for those amino acids that were normally distributed for both groups. P-values obtained from t-test
and Mann-Whitney U test for those amino acids that were normally distributed and not normally distributed, respectively between PLE dogs and appa-
rently, healthy dogs are listed. A Bonferroni correction was applied, so that significance was defined as P< .0017.
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amino acids in PLE dogs because of similar studies performed in human
IBD, which had documented significant changes in amino acids. There-
fore, a control group consisting of 12 apparently healthy dogs was
used for comparison. Unfortunately, because of the small number of
control dogs used, we were unable to breed-match them to the PLE
group. Although a recent study documented no statistically significant
changes in blood tryptophan concentrations between small and larger
dogs,24 further studies should focus on a breed-matched control group
to remove any possible confounding effects from breed variation.
Although the role of prolonged freezing on serum amino acids in dogs
is also unknown, the dogs in the apparently healthy group had serum
stored in 2208C over a similar time period as dogs in the PLE group
and none of the remaining 29 amino acids were shown to be signifi-
cantly different between the 2 groups. One study documented that
storage of human serum at 2208C for up to 26 weeks did not signifi-
cantly affect serum tryptophan concentrations.25 A study reported a
mean and standard deviation (SD) of serum tryptophan concentrations
using high performance liquid chromatography from samples that had
been frozen for a shorter duration (5 months) in 9 clinically healthy
bitches of 5 different breeds as 68.44 and 21.77 nmol/mL, which was
not dissimilar to the results obtained in our apparently healthy group,
using frozen serum stored for a longer duration.26 However, further
studies are needed to determine the effect of prolonged storage in
2208C. Another limitation of our study involved the retrospective
study design, which could have made the interpretation of the clinical
history and assignment of the CCEAI score inconsistent because of
multiple clinician involvement in the cases. In addition, some variables
such as serum cholesterol concentrations or appetite were not
assessed or reported in all cases and 2 dogs did not have intestinal
biopsies performed to definitively diagnose the underlying cause for
the PLE. Therefore, a prospective study to measure serum amino
acids in dogs with PLE would allow consistent assessment of the clin-
ical history for all cases and complete historical and diagnostic infor-
mation as well as negating any potential effect of prolonged storage
of serum on amino acid concentrations. Furthermore, although the
majority of PLE cases in our study had a chronic inflammatory enter-
opathy, additional etiologies were also included; therefore, future
studies should focus on serum tryptophan concentrations in PLE
dogs with similar etiologies to determine if this is influenced by the
underlying pathology.
Although our study did not document a significant change in
concentrations of other serum amino acid between dogs with PLE
and apparently healthy, this might have been because a conserva-
tive test to adjust for multiple comparisons was used resulting in a
stringent P-value to minimize Type 2 error rates. Therefore, future
studies should also focus on those amino acids, such as L-hydroxpro-
line that might have reached significance if a less conservative test
was used, especially in dogs with similar etiologies of PLE and
breed-matched control dogs to determine if they play a role in dis-
ease pathogenesis.
In conclusion, we documented significantly decreased trypto-
phan concentrations in dogs with PLE compared with apparently
healthy dogs. In addition, serum tryptophan concentrations were sig-
nificantly correlated with serum albumin concentrations in dogs with
PLE. Additional studies should be performed to determine serum
kynurenine tryptophan ratio in dogs with PLE to negate any effects
from dietary intake and IDO-1 expression in the intestinal tract to
determine the underlying pathogenesis. In addition, further studies
are needed to determine if correction of serum tryptophan concen-
trations might improve clinical, laboratory or outcome variables in
dogs with PLE.
FIGURE 1 Box and whisker plot of serum tryptophan
concentrations at the time of diagnostic investigation in dogs with
PLE and apparently healthy. Apparently healthy: minimum542
nmol/mL, maximum5135 nmol/mL, median577.5 nmol/mL,
range593 nmol/mL, and interquartile range533 nmol/mL. PLE:
minimum51 nmol/mL, maximum580 nmol/mL, median522
nmol/mL, range579 nmol/mL, and interquartile range517.50
nmol/mL. Serum tryptophan was significantly decreased in dogs
with PLE compared with apparently healthy control dogs (P< .001)
FIGURE 2 Scatter dot plot of serum tryptophan concentrations
(nmol/mL) and serum albumin concentrations (g/L) at the time of
diagnostic investigation in 30 dogs with PLE. Serum tryptophan
concentrations were significantly correlated with serum albumin
concentrations in dogs with PLE (P5 .001, R2 [coefficient of
determination from linear regression analysis]50.506)
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